Making drugs on proteins: Site-directed ligand discovery for fragment-based lead assembly

Current Opinion in Chemical Biology

Volumn 8, Issue 4, 2004, Pages 399-406

  Erlanson, Daniel A ^a   Hansen, Stig K ^a  

^a Sunesis Pharmaceuticals Inc   (United States)

Author keywords

ADC; aspartate decarboxylase; electrospray ionization mass spectrometry; ESI MS; high throughput screening; HTS; IL 2; interleukin 2; MALDI TOF; matrix assisted laser desorption ionization time of flight; methanethiosulfonate; MTS; PTP 1B

Indexed keywords

ALRESTATIN; LIGAND; PEPTIDE; RO 26 4550; UNCLASSIFIED DRUG;

BINDING AFFINITY; COVALENT BOND; DRUG DESIGN; DRUG INDUSTRY; DRUG PROTEIN BINDING; DRUG RESEARCH; GENOMICS; PHYSICAL CHEMISTRY; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN TARGETING; PROTEOMICS; REVIEW; STRUCTURE ACTIVITY RELATION; TECHNOLOGY;

BINDING SITES; DRUG DESIGN; LIGANDS; PEPTIDE FRAGMENTS; PROTEIN BINDING; PROTEINS;

EID: 3342998507     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbpa.2004.06.010     Document Type: Review

References (47)

1. Bohacek R.S., McMartin C., Guida W.C. The art and practice of structure-based drug design: a molecular modeling perspective. Med Res Rev. 16:1996;3-50
2. Erlanson D.A., McDowell R.S., O'Brien T. Fragment-based drug discovery. J Med Chem. 47:2004;3463-3482 A chemo-centric Perspective on this emerging field.
3. McGovern S.L., Caselli E., Grigorieff N., Shoichet B.K. A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. J Med Chem. 45:2002;1712-1722 A watershed paper that provides mechanistic explanations for non-specific inhibition of proteins by high concentrations of small molecules.
4. Rishton G.M. Nonleadlikeness and leadlikeness in biochemical screening. Drug Discov Today. 8:2003;86-96
5. Shuker S.B., Hajduk P.J., Meadows R.P., Fesik S.W. Discovering high-affinity ligands for proteins: SAR by NMR. Science. 274:1996;1531-1534
6. Fejzo J., Lepre C., Xie X. Application of NMR screening in drug discovery. Curr Top Med Chem. 3:2003;81-97
7. Homans S.W. NMR spectroscopy tools for structure-aided drug design. Angew Chem Int Ed Engl. 43:2004;290-300
8. Sharff A., Jhoti H. High-throughput crystallography to enhance drug discovery. Curr Opin Chem Biol. 7:2003;340-345
9. Tethering is a service mark of Sunesis Pharmaceuticals, Inc. for its fragment-based drug discovery.
10. Erlanson D.A., Braisted A.C., Raphael D.R., Randal M., Stroud R.M., Gordon E.M., Wells J.A. Site-directed ligand discovery. Proc Natl Acad Sci USA. 97:2000;9367-9372
11. Erlanson D.A., Wells J.A., Braisted A.C. Tethering: fragment-based drug discovery. Annu Rev Biophys Biomol Struct. 33:2004;199-223 A thorough review of the theory and practice of Tethering.
12. Toogood P.L. Inhibition of protein-protein association by small molecules: approaches and progress. J Med Chem. 45:2002;1543-1558
13. Berg T. Modulation of protein-protein interactions with small organic molecules. Angew Chem Int Ed Engl. 42:2003;2462-2481
14. Arkin M.R., Wells J.A. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat Rev Drug Discov. 3:2004;301-317 An exhaustive recent review discussing the state of the art in this field.
15. Nelson B.H., Willerford D.M. Biology of the interleukin-2 receptor. Adv Immunol. 70:1998;1-81
16. Tilley J.W., Chen L., Fry D.C., Emerson S.D., Powers G.D., Biondi D., Varnell T., Trilles R., Guthrie R., Mennona F., et al. Identification of a small molecule inhibitor of the IL-2/IL-2Ra receptor interaction which binds to IL-2. J Am Chem Soc. 119:1997;7589-7590
17. Arkin M.R., Randal M., DeLano W.L., Hyde J., Luong T.N., Oslob J.D., Raphael D.R., Taylor L., Wang J., McDowell R.S., et al. Binding of small molecules to an adaptive protein-protein interface. Proc Natl Acad Sci USA. 100:2003;1603-1608
18. Hyde J., Braisted A.C., Randal M., Arkin M.R. Discovery and characterization of cooperative ligand binding in the adaptive region of interleukin-2. Biochemistry. 42:2003;6475-6483
19. Braisted A.C., Oslob J.D., Delano W.L., Hyde J., McDowell R.S., Waal N., Yu C., Arkin M.R., Raimundo B.C. Discovery of a potent small molecule IL-2 inhibitor through fragment assembly. J Am Chem Soc. 125:2003;3714-3715 The first report of a nanomolar inhibitor of a protein-protein interaction discovered using Tethering.
20. Thanos C.D., Randal M., Wells J.A. Potent small-molecule binding to a dynamic hot spot on IL-2. J Am Chem Soc. 125:2003;15280-15281
21. Erlanson D.A., Lam J.W., Wiesmann C., Luong T.N., Simmons R.L., DeLano W.L., Choong I.C., Burdett M.T., Flanagan W.M., Lee D., et al. In situ assembly of enzyme inhibitors using extended tethering. Nat Biotechnol. 21:2003;308-314 The first complete description of Tethering with extenders.
22. Allen D.A., Pham P., Choong I.C., Fahr B., Burdett M.T., Lew W., DeLano W.L., Gordon E.M., Lam J.W., O'Brien T., et al. Identification of potent and novel small-molecule inhibitors of caspase-3. Bioorg Med Chem Lett. 13:2003;3651-3655
23. Choong I.C., Lew W., Lee D., Pham P., Burdett M.T., Lam J.W., Wiesmann C., Luong T.N., Fahr B., DeLano W.L., et al. Identification of potent and selective small-molecule inhibitors of caspase-3 through the use of extended tethering and structure-based drug design. J Med Chem. 45:2002;5005-5022
24. Johnson T.O., Ermolieff J., Jirousek M.R. Protein tyrosine phosphatase 1B inhibitors for diabetes. Nat Rev Drug Discov. 1:2002;696-709
25. Erlanson D.A., McDowell R.S., He M.M., Randal M., Simmons R.L., Kung J., Waight A., Hansen S.K. Discovery of a new phosphotyrosine mimetic for PTP1B using breakaway tethering. J Am Chem Soc. 125:2003;5602-5603
26. Obita T., Muto T., Endo T., Kohda D. Peptide library approach with a disulfide tether to refine the Tom20 recognition motif in mitochondrial presequences. J Mol Biol. 328:2003;495-504
27. Huc I., Lehn J-M. Virtual combinatorial libraries: dynamic generation of molecular and supramolecular diversity by self-assembly. Proc Natl Acad Sci USA. 94:1997;2106-2110
28. Hochgurtel M., Kroth H., Piecha D., Hofmann M.W., Nicolau C., Krause S., Schaaf O., Sonnenmoser G., Eliseev A.V. Target-induced formation of neuraminidase inhibitors from in vitro virtual combinatorial libraries. Proc Natl Acad Sci USA. 99:2002;3382-3387 A proof-of-concept study of dynamic combinatorial chemistry to generate potent inhibitors of an enzyme.
29. Hochgurtel M., Biesinger R., Kroth H., Piecha D., Hofmann M.W., Krause S., Schaaf O., Nicolau C., Eliseev A.V. Ketones as building blocks for dynamic combinatorial libraries: highly active neuraminidase inhibitors generated via selection pressure of the biological target. J Med Chem. 46:2003;356-358
30. Webb ME, Stephens E, Smith AG, Abell C: Rapid screening by MALDI-TOF mass spectrometry to probe binding specificity at enzyme active sites. Chem Commun 2003:2416-2417.
31. Albert A., Dhanaraj V., Genschel U., Khan G., Ramjee M.K., Pulido R., Sibanda B.L., von Delft F., Witty M., Blundell T.L., et al. Crystal structure of aspartate decarboxylase at 2.2 Å resolution provides evidence for an ester in protein self-processing. Nat Struct Biol. 5:1998;289-293
32. Smar M.W., Ares J.J., Nakayama T., Itabe H., Kador P.F., Miller D.D. Selective irreversible inhibitors of aldose reductase. J Med Chem. 35:1992;1117-1120
33. Chmura A.J., Orton M.S., Meares C.F. Antibodies with infinite affinity. Proc Natl Acad Sci USA. 98:2001;8480-8484
34. Levitsky K., Ciolli C.J., Belshaw P.J. Selective inhibition of engineered receptors via proximity-accelerated alkylation. Org Lett. 5:2003;693-696
35. Chen G., Heim A., Riether D., Yee D., Milgrom Y., Gawinowicz M.A., Sames D. Reactivity of functional groups on the protein surface: development of epoxide probes for protein labeling. J Am Chem Soc. 125:2003;8130-8133
36. Johnson J.L., Cusack B., Hughes T.F., McCullough E.H., Fauq A., Romanovskis P., Spatola A.F., Rosenberry T.L. Inhibitors tethered near the acetylcholinesterase active site serve as molecular rulers of the peripheral and acylation sites. J Biol Chem. 278:2003;38948-38955
37. Lewis W.G., Green L.G., Grynszpan F., Radic Z., Carlier P.R., Taylor P., Finn M.G., Sharpless K.B. Click chemistry in situ: acetylcholinesterase as a reaction vessel for the selective assembly of a femtomolar inhibitor from an array of building blocks. Angew Chem Int Ed Engl. 41:2002;1053-1057
38. Kolb H.C., Sharpless K.B. The growing impact of click chemistry on drug discovery. Drug Discov Today. 8:2003;1128-1137
39. Muir T. Semisynthesis of proteins by expressed protein ligation. Annu Rev Biochem. 72:2003;249-289 A comprehensive review of a widely applicable technology, although not explicitly used for site-directed ligand discovery.
40. Cook B.N., Bertozzi C.R. Chemical approaches to the investigation of cellular systems. Bioorg Med Chem. 10:2002;829-840
41. Campbell D.A., Szardenings A.K. Functional profiling of the proteome with affinity labels. Curr Opin Chem Biol. 7:2003;296-303
42. Jeffery D.A., Bogyo M. Chemical proteomics and its application to drug discovery. Curr Opin Biotechnol. 14:2003;87-95
43. Adam G.C., Sorensen E.J., Cravatt B.F. Chemical strategies for functional proteomics. Mol Cell Proteomics. 1:2002;781-790
44. Perret P., Laube B., Schemm R., Betz H., Goeldner M., Foucaud B. Affinity labeling of cysteine-mutants evidences contact residues in modeled receptor binding sites. J Recept Signal Transduct Res. 22:2002;345-356
45. Ramstrom O., Lehn J.M. Drug discovery by dynamic combinatorial libraries. Nat Rev Drug Discov. 1:2002;26-32
46. Rowan S.J., Cantrill S.J., Cousins G.R.L., Sanders J.K.M., Stoddart J.F. Dynamic covalent chemistry. Angew Chem Int Ed Engl. 41:2002;898-952
47. Raimundo B.C., Oslob J.D., Braisted A.C., Hyde J., McDowell R.S., Randal M., Waal N.D., Wilkinson J., Yu C.H., Arkin M.R. Integrating fragment assembly and biophysical methods in the chemical advancement of small-molecule antagonists of IL-2: an approach for inhibiting protein-protein interactions. J Med Chem. 47:2004;3111-3130